Literature DB >> 9834816

Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

E A Eisenhauer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9834816     DOI： 10.1023/a:1008497110734

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

Review 1.  Development of target-based antineoplastic agents.

Authors:  W M Stadler; M J Ratain
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.

Authors:  Kenichiro Enooku; Ryosuke Tateishi; Fumihiko Kanai; Yuji Kondo; Ryota Masuzaki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2011-09-21       Impact factor: 7.527

Review 3.  Clinical trial design for target specific anticancer agents.

Authors:  Ronald Hoekstra; Jaap Verweij; Ferry A L M Eskens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 4.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 5.  Targeted therapies for gynecologic malignancies.

Authors:  Johnny Hyde; D Scott McMeekin
Journal:  Curr Treat Options Oncol       Date:  2005-03

Review 6.  Prospective clinical trials of brain tumor therapy: the critical role of neurosurgeons.

Authors:  Frederick F Lang; Anthony Asher
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 7.  The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents.

Authors:  E K Rowinsky
Journal:  Drugs       Date:  2000       Impact factor: 9.546

8.  Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin.

Authors:  R S Herbst; A T Lee; H T Tran; J L Abbruzzese
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.075

Review 9.  Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.

Authors:  Tatiana Vidaurre; Julia Wilkerson; Richard Simon; Susan E Bates; Tito Fojo
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360

10.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.

Authors:  P G Casali; P Bruzzi; J Bogaerts; J-Y Blay
Journal:  Ann Oncol       Date:  2014-10-01       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.